SCHEMBL31030934

CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)[C@@H](C)O)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 4)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	14/20	0.57

▸	OPRM1	P35372	4/20	0.55

▸	OPRD1	P41143	4/20	0.55

▸	OPRK1	P41145	3/20	0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30918524	0.99	GLP1R (0.58)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL30299020	0.99	GLP1R (0.58)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL30368416	0.96	OPRM1 (0.56)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL30080556	0.95	OPRM1 (0.61)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL30407947	0.95	OPRM1 (0.55)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL31256793	0.94	OPRM1 (0.55)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL31467321	0.93	OPRM1 (0.62)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL31256795	0.92	OPRM1 (0.57)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL31062669	0.91	GLP1R (0.65)	GLP1ROPRM1OPRD1OPRK1
SCHEMBL29722072	0.91	GLP1R (0.65)	GLP1ROPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20250019410-A1	PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF	SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN)	2025-01-16	—	—	US	disclosed
CN-118240059-A	Polypeptide synthesis method	深圳翰宇药业股份有限公司	2024-06-25	—	—	CN	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20250019410-A1	PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF	SYK, TREH, QDPR	GLP1R 1030/4885OPRM1 4271/4885OPRD1 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.